https://www.selleckchem.com/pr....oducts/prostaglandin
84; 95% CI, -5.56 to -0.12; I =50%). The rate of invasive mechanical ventilation (MV) was lower in the patients who used JAK inhibitors than among the controls. Finally, no significant difference was observed between the patients who used JAK inhibitors and the controls in the risk of any adverse events (OR, 0.92; 95% CI, 0.64-1.34; I =33%) and serious adverse events (OR, 0.80; 95% CI, 0.45-1.44; I =46%). JAK inhibitors can lead to a better clinical outcome of hospitalized COVID-19 patients, and they are a safe agent i